Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Phase I study of ASC30 once-daily tablets is a randomized, double-blind, placebo-controlled, single ascending dose (6 cohorts) and multiple ascending dose (3 cohorts, 28 daily oral doses) study to evaluate the safety, tolerability, PK and efficacy of ASC30 in participants with obesity

Next Previous
X
Search
Trial Profile

The Phase I study of ASC30 once-daily tablets is a randomized, double-blind, placebo-controlled, single ascending dose (6 cohorts) and multiple ascending dose (3 cohorts, 28 daily oral doses) study to evaluate the safety, tolerability, PK and efficacy of ASC30 in participants with obesity

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ASC 30 (Primary)
  • Indications Obesity
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

    • Most Recent Events

    • 24 Sep 2024 New trial record
    • 17 Sep 2024 According to Ascletis media release, the Company expects topline data from the study in the first quarter of 2025.
    • 17 Sep 2024 Results from cohort 1 (n=8) presented in an Ascletis media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top